JW
JW신약 Stock: price and insider trades · South Korea
JW신약: what insiders have been doing
We have very little insider data for JW신약 so far. With so few records, no pattern can be drawn yet. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
n/a
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 1,486 of 26,911 companies
78.3
score / 100
Value92
Quality65
FCF yld16%
Earn yld17%
EV/EBITDA4.2x
ROE14%
Gross mgn28%
Net mgn11%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩11,090
Analyst consensus
Income statement
Revenue₩257.8B
Gross profit₩72.3B28% margin
EBITDA₩52.8B20% margin
Net income₩28.6B11.5% margin
Valuation
Beta0.24
Balance sheet & cash
Market cap₩171.7B
Total debt₩50.6B
Free Cash Flow₩27.1B
Debt / Equity19%
Profitability & ownership
ROE14.0%
ROA6.5%
% insiders43.7%
% institutions11.5%
Declarations0 total
No declarations found
0 of 0 declarations
About JW신약
JW신약 is a healthcare and pharmaceutical company listed on the XKRX. It specializes in the development and commercialization of innovative drugs.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
